Total Funding
59
Total FundingSeries B raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
125411
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
- Mamoun Alhamadsheh: Scientific co-Founder
Uma Sinha: Chief Scientific OfficerPast Role: Global Blood Therapeutics, Chief Scientific Officer
About the Company
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
Women Founded
